Amgen Ventures — Full Portfolio
7 tracked investments · listed companies and verified rows first
Cartography develops antibody-based cancer therapies using single-cell sequencing and computational biology to identify precise cellular targets.
AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US
Max Mumbach(Founding Scientist, Target Discovery)Jeffrey Verboon(Founding Scientist, Computational Biology)Ansu Satpathy(Founder)Kevin Parker, PhD(Chief Executive Officer, Board Director; co-founder)Ansuman Satpathy, MD, PhD(Co-founder; Board Director)Howard Chang(Co-founder)
Co-investors8VCAndreessen HorowitzArtis VenturesGlobal BioAccess FundHAWKTAILPfizer Venture Investments+6 more
Ember Life Sciences applies its temperature-control heating and cooling technology to healthcare logistics through the Ember Cube, a self-refrigerated, cloud-based shipping box with real-time location tracking and temperature monitoring for cold-chain payloads at 2°C–8°C.
HealthtechIoTLogistics & Supply ChainWestlake Village, US
Clayton Alexander(Executive Officer, Director)Brian Bejarano(Executive Officer)Ann Marie Hyllengren(Executive Officer)
BoardMichael Kaufmann(Director)Timothy White(Director)James DeNaut(Director)
Co-investorsCarrier VenturesSea Court CapitalTDF Ventures
Gandeeva Therapeutics uses AI, machine learning, and atomic-resolution cryo-EM imaging to map druggable protein interactions and design molecular glues that bind at specific protein interfaces.
AI & Machine LearningBiotechDeep TechDigital Health
Sriram Subramaniam(Founder)in
Co-investorsAir Street CapitalLux CapitalObvious VenturesLeaps by Bayer
HealthtechSan Carlos, US
Hugh Y. Rienhoff(Executive Officer, Director)Laura G. Eichorn(Executive Officer)
BoardPatrick Heron(Director)inDennis Henner(Director)Alan Sachs(Director)
Co-investorsClarus VenturesFrazier Healthcare PartnersFrazier Life Sciences
HealthtechPhoenix, US
MARK L. WHITEHOUSE(Executive Officer)MITCHELL A. FOSTER(Executive Officer, Director, Promoter)Mark Whitehouse(Executive Officer, Director, Promoter)Nicholas Theodore(Director)Mitchell Foster(Executive Officer, Director, Promoter)Joel Barthelemy(Director)
Co-investorsGrayhawk CapitalAZ Venture Capital Inc.NOVA PrimeQuesta CapitalXcellerant Ventures
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)Roet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)Jason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)
Co-investorsDroia VenturesMC Healthcare VenturesMission BiocapitalMitsui Global InvestmentSanofi VenturesSV Health Investors+6 more
Develops programmable mRNA therapies that last longer and target cells more precisely for cancer and other diseases.
BiotechBoston, US
Tasuku Kitada(Executive Officer, Director, Promoter)inJacob Becraft(Executive Officer, Director, Promoter)inSamta Kundu(Executive Officer)in
BoardJeb Keiper(Director)Ala Alenazi(Director)Pegah Ebrahimi(Director)
Co-investorsJIC Venture Growth InvestmentsKinnevikPlayground GlobalANRIFPVICONIQ+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.